탄저 백신 시장 : 유형, 용도, 최종 용도별, 예측(2024-2032년)

Global Anthrax Vaccine Market will witness 5.4% CAGR between 2024 and 2032, driven by increasing investments in vaccine production. Governments and private sector stakeholders are recognizing the critical need for effective vaccination against anthrax, a serious bacterial infection that can be used as a bioterrorism weapon. Consequently, significant funds are being directed towards research, development, and manufacturing of advanced anthrax vaccines.

For instance, in January 2024, The US Department of Defense (DoD) awarded Emergent BioSolutions a procurement contract valued at up to $235.8 million for an indefinite-delivery and indefinite-quantity (IDIQ) supply of BioThrax. Under this contract, Emergent will provide BioThrax to all US military personnel at high risk of anthrax exposure.

The growing public health awareness and government initiatives are fueling market growth. Investments are not only enhancing vaccine availability but also ensuring improved production techniques, higher efficacy, and greater accessibility. Additionally, the COVID-19 pandemic has underscored the importance of robust vaccine infrastructure, prompting further investments into facilities capable of producing a wide range of vaccines, including those for anthrax. As a result, the anthrax vaccine market is poised for substantial growth, underpinned by financial commitments aimed at safeguarding public health and national security.

The overall Anthrax Vaccine Industry value is classified based on the type, application, end-use, and region.

The anthrax vaccine market revenue from the live attenuated vaccine segment will register a commendable CAGR from 2024 to 2032. These vaccines, which contain a weakened form of the bacterium that causes anthrax, provide strong and long-lasting immunity. Their efficacy and ability to induce a robust immune response make them highly sought after, particularly in regions with high anthrax exposure risks. Investments in biotechnology and advanced vaccine production techniques have further bolstered the market. Live attenuated vaccines offer a reliable solution for military personnel, agricultural workers, and populations in endemic areas, driving substantial growth in the anthrax vaccine market.

The human use segment will witness an appreciable growth from 2024 to 2032. Governments and health organizations are prioritizing the vaccination of high-risk groups, such as military personnel and laboratory workers. Advances in vaccine technology and heightened public health awareness have led to increased investments in research and production. Furthermore, regulatory approvals and strategic stockpiling initiatives by various countries are bolstering market demand. As a result, the anthrax vaccine market for human use is experiencing significant growth, ensuring preparedness and safeguarding public health.

Europe anthrax vaccine market will exhibit a notable CAGR from 2024 to 2032. European governments are investing in advanced vaccine production and stockpiling to protect high-risk populations, such as military personnel and emergency responders. The European Union's regulatory support and funding for vaccine research and development are further propelling market growth. Additionally, collaborations between biotech companies and public health institutions are enhancing vaccine availability and efficacy. This proactive approach ensures Europe is well-prepared to mitigate the risks of anthrax outbreaks, driving sustained demand in the anthrax vaccine market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing burden of anthrax globally
    • 3.2.1.2 Technology advancements in the vaccine development
    • 3.2.1.3 Increased globalization and travel
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of awareness for diagnostic test of target disease
    • 3.2.2.2 High cost of vaccine
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cell free PA vaccine
  • 5.2.1 Anthrax vaccine absorbed (AVA)
  • 5.2.2 Anthrax vaccine precipitated (AVP)
• 5.3 Live attenuated vaccine

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Veterinary use
• 6.3 Human use

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Veterinary hospitals & clinics
• 7.3 Hospital & clinics
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Altimmune Inc.
• 9.2 Agrovet
• 9.3 Bayer AG
• 9.4 Bavarian Nordic
• 9.5 Biogenesis Bago SA
• 9.6 Ceva Sante Animale
• 9.7 Colondo Serum Company
• 9.8 Emergent BioSolutions
• 9.9 Elusys Therapeutics Inc.
• 9.10 Indian Immunologicals Ltd.
• 9.11 Intervac (PVT) Ltd
• 9.12 JOVAC
• 9.13 Merck Co, Inc.
• 9.14 Proton Biopharma Ltd.